Effects of Glimepiride vs Glibenclamide on Ischaemic Heart Disease Risk Factors and Glycaemic Control in Patients with Type 2 Diabetes Mellitus

  title={Effects of Glimepiride vs Glibenclamide on Ischaemic Heart Disease Risk Factors and Glycaemic Control in Patients with Type 2 Diabetes Mellitus},
  author={M. Britton and A. E. Denver and V. Mohamed-ali and J. Yudkin},
  journal={Clinical Drug Investigation},
AbstractObjective: This study aimed to compare the effects of glimepiride and glibenclamide on glycaemic control and a range of risk factors for ischaemic heart disease (IHD), including concentrations of insulin-like molecules. Patients: A double-blind, placebo-controlled, randomised, crossover comparison of 4 weeks of treatment with glibenclamide 2.5 to 20 mg/day and glimepiride 1 to 8 mg/day was undertaken in 29 type 2 (non-insulin-dependent) diabetic patients. The average (mean ±SD… Expand
The effects of oral anti‐hyperglycaemic medications on serum lipid profiles in patients with type 2 diabetes
This review compares the effects of OAMs on serum lipids [total cholesterol (TC), low‐density lipoprotein cholesterol (LDL‐C), high‐density cholesterol (HDL-C), triglycerides (TGs) and free fatty acids (FFAs) in patients with type 2 diabetes. Expand
Insulin, glucagon, and hypoglycemic drugs
The various symptoms of hypoglycemia have been reviewed in the chapter, including detailed descriptions of autonomic symptoms, neuroglycopenic Symptoms, general malaise, unawareness symptoms in adults, children, pregnancy, elderly people, and type 2 diabetes, and combinations with other medications. Expand
Effects of sulfonylurea treatment on blood plasminogen activator inhibitor-1 levels in patients with type 2 diabetes mellitus: A network meta-analysis
The effects of three types of sulfonylureas (glibenclamide, gliclazide, and glimepiride) on blood plasminogen activator inhibitor-1 levels in patients with type2 diabetes mellitus are compared. Expand
Glimepiride reduces mononuclear activation of the redox‐sensitive transcription factor nuclear factor‐kappa B
In vitro and in vivo in a placebo‐controlled study the effect of glimepiride on the redox‐sensitive transcription factor nuclear factor‐kappa B (NF‐κB) is studied. Expand


Long-term treatment of type 2 diabetic patients with the new oral antidiabetic agent glimepiride (Amaryl): a double-blind comparison with glibenclamide.
The long-term follow-up confirmed that glimepiride (1-8 mg) once daily provides equivalent metabolic control to a higher dosage (2.5-20.0 mg) of glibenclamide. Expand
How Does Glibenclamide Lower Plasma Glucose Concentration in Patients with Type 2 Diabetes?
It is proposed that the increase in ambient insulin level was primarily responsible for the decline in plasma glucose level following glibenclamide therapy, possibly by lowering plasma NEFA concentrations. Expand
In vivo action of glibenclamide in obese subjects with mild type 2 (non-insulin dependent) diabetes.
In order to evaluate whether the hypoglycaemic action of glibenclamide during chronic treatment of obese subjects with NIDDM is primarily due to changes in the daytime insulin level, in insulinExpand
Effects of glibenclamide on serum lipids, lipoproteins, thromboxane, beta-thromboglobulin, and prostacyclin in non-insulin-dependent diabetes mellitus.
The results demonstrate the favorable effect of glibenclamide on lipoproteins and apolipoproteins in NIDDM patients, especially in increasing HDL-C levels and LDL-C%, and in attenuating platelet aggregation as indicated by reduction of TXB2 and B-TGL. Expand
Effects of glimepiride on in vivo insulin action in normal and diabetic rats.
It is suggested that glimepiride enhances insulin action in peripheral tissues, and that glIMEpiride treatment with insulin improves the insulin resistance observed in streptozotocin-induced diabetic rats. Expand
Mechanism of Improvement in Glucose Metabolism After Chronic Glyburide Therapy
Results indicate that improved glucose tolerance in NIDDM after glyburide results from both enhanced tissue sensitivity to insulin and increased insulin secretion, and the primary mechanism responsible for the improvement in glucose metabolism in young controls wasEnhanced tissue sensitivity tO insulin. Expand
Effect of Sulphonylurea Therapy on Plasma Insulin, Intact and 32/33 Split Proinsulin in Subjects with Type 2 Diabetes Mellitus
It is clear from this work that sulphonylureas have a complex effect on beta cell physiology and as well as stimulating release of insulin they increase the release of intact proinsulin but not that of 32/33 split proins insulin, hence they increaseThe intact to 32/ 33 split pro Insulin ratio. Expand
Chronic chlorpropamide therapy of noninsulin-dependent diabetes augments basal and stimulated insulin secretion by increasing islet sensitivity to glucose.
It is concluded that chronic chlorpropamide therapy augments both basal and stimulated insulin secretion in NIDDM and that this may be an important mechanism of the drug's hypoglycemic effect. Expand
The Sulfonylurea Drug, Glimepiride, Stimulates Glucose Transport, Glucose Transporter Translocation, and Dephosphorylation in Insulin-Resistant Rat Adipocytes In Vitro
It is concluded that glimepiride activates glucose transport by stimulation of GLUT1 and GLUT4 translocation in rat adipocytes via interference at a site downstream of the putative molecular defect in the signaling cascade between the insulin receptor and the glucose transport system induced by high concentrations of glucose and insulin. Expand
Effects of an oral antidiabetic drug on the fibrinolytic system of blood in insulin-treated diabetic patients.
It is concluded that gliclazide induces small, but significant, non-insulin-dependent extrametabolic effects on the extrinsic (t-PA) and intrinsic (prekallikrein) system of fibrinolysis. Expand